If you have a burning desire to respond to a paper published in ADC or FEH, why not make use of our “rapid response” option? Log on to our website (www.archdischild.com), find the paper that interests you, click on “full text” and send your response by email by clicking on “submit a response”.

Providing it isn’t libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on “read eletters” on our homepage.

The editors will decide, as before, whether to also publish it in a future paper issue.

Problems with scoring bruises

We write to draw attention to two problems with the recent study on a scoring system for bruising by Dunstan et al.1

Firstly, the authors did not publish confidence intervals for the likelihood ratios (LRs) derived from different score threshold values (table 3), thereby not allowing readers to judge whether the LRs are statistically—let alone clinically—significant.

Secondly, the authors neglect the phenomenon of spectrum bias. This is a well described feature of many tests, whereby sensitivity and specificity (and hence derived LRs) of a test vary with disease severity or prevalence.

Examples of spectrum bias have been described with several tests including exercise stress testing2 and UTI diagnosis.3

The study population had a prevalence of physical abuse of 40%, much higher than the general paediatric population. Since test performance—that is, LR—is not independent of the pre-test probability, the LRs generated by a study done on this population cannot necessarily be used in a population with a much lower prevalence of abuse, as the authors have done in table 4. Since spectrum bias tends to reduce test performance as the pre-test probability falls,4 the LR for any given score threshold would be smaller than that quoted when applied to a population with a lower prevalence of physical abuse.

As most settings would expect to have a lower prevalence of physical abuse than the study, this reduces the value of the proposed scoring system as a clinical tool.

M Williams
Intensive Care Unit, Charing Cross Hospital,
London, W6 8RF, UK

B Krishnan
Department of Paediatrics, Guy’s Hospital,
London SE1 9RT, UK

References

Does cefotaxime eradicate nasopharyngeal carriage of N meningitidis

We enrolled 43 children admitted with an unexplained clinical diagnostic meningococcal sepsis into a study to determine whether cefotaxime eradicated nasopharyngeal carriage of N meningitidis. In 28 cases (70%) the diagnosis was confirmed by positive culture from blood, nose, throat, or skin scraping, detection of meningococcal DNA in blood by polymerase chain reaction, or convalescent meningococcal serology. All children were treated with intravenous cefotaxime for seven days.

On admission, the throat and nasopharyngeal swabs were both positive for meningococcus in two patients; in another two patients, the nasopharyngeal swab was positive while the throat swab was negative. In three patients the swabs became negative after 24 hours of treatment, and in one child it became negative after 48 hours. In these children and others in whom the swabs were negative from the day of admission, subsequent swabs remained negative.

Compared to a previous study5 that reported a nasopharyngeal carriage rate of 50% on admission and showed that the yield of meningococci in throat swabs was unaffected by prior administration of penicillin, the yield from throat and nose swabs in this study (9.5%) was poor. This may reflect the fact that in practice the yield from throat and nose swabs is low, and that the swabs are not taken after the child has been given the first dose of cefotaxime. The finding suggests that cefotaxime, like other antibiotics,6 is effective in eradicating nasopharyngeal carriage, and in children treated with cefotaxime, additional prophylaxis with rifampicin is not necessary. However, no recommendations for the use of cefotaxime alone can emanate from these findings as the sample size was small and study design did not compare cefotaxime with gold standard treatment (either rifampicin or ceftriaxone). We are keen to coordinate a follow up multicentre study this winter involving paediatric intensive care units across the country to compare the efficacies of ceftriaxone with cefotaxime on eradication of meningococcal carriage. Interested units are kindly requested to contact us.

J Clark, R Lakshman, A Galloway, A Cant
Newcastle General Hospital, UK

References

Pneumocystis carinii pneumonia in an infant with transient hypogammaglobulinaemia of infancy

Transient hypogammaglobulinaemia of infancy (THI) is characterised by prolongation of the physiological decline in serum immunoglobulin concentrations seen in the first six months of life.7 The incidence reported from an Australian paediatric centre was estimated as 23 per 10,000 live births.8 It has been reported that THI does not usually predispose to significant infection.9

A male infant born at term to non-consanguineous parents presented at 3.5 months of age with cough, tachypnoea (70 breaths/minute), wheeze, crepitations, and hypoxia. A chest X-ray and radiograph showed hyperinflation, patchy opacification in the hilar regions and upper lobes. Pneumocystis carinii was identified in bronchoalveolar lavage by toluidine blue staining. The immunological findings of this child were consistent with those of THI with an IgG level less than the fifth centile7 and absent serum IgA,7 which resolved with age (IgG at presentation 3.9 g/l (normal: 1.39–8.04); at 5 months 2.23 (1.39–8.04); at 10 months 1.77 (2.02–11.76); at 17 months 7.51 (2.71–13.78); IgA at 5 months <0.07 g/l (normal: 0.14–0.69); at 13 months 0.14 (0.17–1.34) and evidence of specific antibody production to tetanus, diphtheria, and Haemophilus influenza type b following immunisation.1 T cell numbers (total lymphocytes 6.2 x 10⁹, CD3 68%, CD4 56%, CD8 15%) and phytohaemagglutinin induced proliferation were normal. At 3 years the child was well with normal IgG, IgA, and IgM levels.

Pneumocystis carinii pneumonia presenting in the first three months of life is an infection typically seen in patients with significant T cell immunodeficiencies and X linked hyper IgM. These were excluded by normal T cell numbers and function and by normal CD40 ligand expression and mutation analysis. There are reports of Pneumocystis carinii pneumonia in immunocompetent infants10 and agammaglobulinaemia.11 This is the first description of Pneumocystis carinii pneumonia in a patient with THI.

J M Smart, A S Kemp
Department of Immunology, Royal Children’s Hospital, Flemington Road, Parkville 3052, Australia; kemp@cryptic-rch.unimelb.edu.au

D S Armstrong
Department of Respiratory Medicine, Royal Children’s Hospital

References

www.archdischild.com
Procalcitonin as a prognostic marker in children with meningococcal septic shock

Carrol and coworkers\(^1\) reported from Karabocuoglu et al\(^{1,2}\) who confirmed that procalcitonin (PCT) was higher in children with severe meningococcaemia (fever, petechiae or purpura, and hemodynamic instability) than in children with systemic meningococcal infection without shock (291.29 ± 167 v 19.7 ± 23 ng/ml; p<0.001).\(^3\)

Unfortunately, information is lacking in the report of Carrol et al,\(^1\) namely: a clear definition of severe MCD (defined in their paper as a Glasgow Meningococcal Septicaemia Prognostic Score >8) and median PCT values.\(^1\) We therefore investigated 35 children (median age: 16 months; Q1:9–Q3:45) with MSS, who were admitted or at the time of death. Predictive value, sensitivity, specificity, positive and negative predictive values, and percentage of wellclassified children were calculated at the following cut-off values: PCT >130 ng/ml (the best cutoff value of the PCT level was determined by \(\chi^2\) optimisation (Fisher’s test; p=0.004)), CRP <100 mg/l, PRISM value >20 and PRISM value of the PCT level was determined by \(\chi^2\) tests.\(^4\)

In our study, PCT on admission was as accurate and PRISM probability of death calculated within 24 hrs of admission or at the time of death, and more accurate than the CRP level in classifying survivors and nonsurvivors of MSS. These results accord with those of Hatherill et al\(^5\) who, in 37 children with MSS, that admission PCT level (values not indicated) was higher in nonsurvivors (11%) than in survivors (p=0.04) and related to severity of organ failure. However, in the whole group of children with septic shock whatever the causative organism, admission PCT functioned worse than the PRISM score (AUC 0.73 (0.59–0.88) vs 0.70 (0.71–0.93); statistical comparison not performed).\(^6\) The PRISM score is accepted in PICUs worldwide and has been reported to accurately predict outcome of meningococcal disease.\(^7\) However, as it needs a 24 hr observation period, it cannot be used as an inclusion criterion for clinical trials. Admission PCT could represent a good alternative tool if future studies confirm its ability to predict mortality.

Table 1 Performance characteristics of PCT, CRP, and PRISM score in 35 children with MSS

<table>
<thead>
<tr>
<th>Severity index (%)</th>
<th>PCT</th>
<th>CRP</th>
<th>PRISM value</th>
<th>PRISM probability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>65</td>
<td>46</td>
<td>83</td>
<td>83</td>
</tr>
<tr>
<td>Specificity</td>
<td>63</td>
<td>46</td>
<td>73</td>
<td>73</td>
</tr>
<tr>
<td>Positive predictive value</td>
<td>71</td>
<td>55</td>
<td>65</td>
<td>65</td>
</tr>
<tr>
<td>Negative predictive value</td>
<td>55</td>
<td>35</td>
<td>55</td>
<td>55</td>
</tr>
</tbody>
</table>

Table 1 Performance characteristics of PCT, CRP, and PRISM score in 35 children with MSS

References

Incidence of severe and fatal reactions to foods

Although the article by Macdougall et al\(^\dagger\) regarding the incidence of severe and fatal reactions to food would be seem to be reassuring, we would like to express some concerns and raise some questions about the data presented. The first question is whether the ascertainment of cases is really as complete as the authors suggest. We acknowledge that the UK medical system may allow better reporting and access to mortality data than that of the US. However, the records acquired as described seem to represent the same underlying issues as those in the US. It is really unlikely that the BPSU misses a significant number of cases? Based upon a well characterised population in Olmstead county Minnesota and extrapolating the data to a US population of 280 million, it may be estimated that there are 200 deaths from anaphylaxis reactions to food each year.\(^\dagger\)

A paper published in 2001, described methodology in which a National Registry had been established and was well publicised to US allergists.\(^\dagger\) Very few reports were made by allergists and none by other physicians. No cases were initially reported by physicians who conduct research in food allergy. Nearly all the cases were ascertained from the press. These news articles appeared in local newspapers and were not reported in media with a large regional or national circulation. In an earlier effort to account for all cases of food anaphylaxis, only in Colorado, a significantly

www.archdischild.com
higher number of cases were reported from rural regions as compared to metropolitan areas strongly suggesting either misdiagnosis or inaccurate recording of cases in the emergency department log of busy hospitals. A second concern is the reporting of cases only up to age 15. In the paper mentioned above, of 32 fatalities 10 occurred in young- sters up to age 15. An additional 10 occurred in adolescents aged 16 to 19. Why did MacDougall et al not include all adolescents? A third question must always be raised when fatal food anaphylaxis is studied. Is it not possible that cases of fatal asthma were actually initiated by unidentified allergic reactions to food? All authors in this field are likely to agree that the ultimate cause of death may be irreversible airway obstruction, and all would agree that poorly controlled asthma increases the risk of fatal anaphylactic reac- tions to food, but we would suggest that the trigger responsible for individual asthma fatalities is not always determined. What about fatalities that never reach the emer- gency department and are misclassified on death certificates as asthma fatalities? Indi- viduals that die at home and are classified as asthma deaths are unlikely to be further investigated whether the US or the UK. Fourthly, the authors’ definition of severity seems incomplete. Individuals with severe food reactions who self-administer epineph- rine often do not go to hospital, are less likely to have reactions that require hospital- ization or cause death, and often they do not report these reactions to their physicians unless specifically queried. Some survive the reaction without treatment, become convinced that they have an allergy to a specific food, and never tell their physician. We could argue about the possible progression of these epi- sodes to near fatal or fatal reactions, but the point we wish to make is that they are rarely under reported. The fifth issue concerns the safe administration of epinephrine. We dis- agree about the risk to children of the administration of a single dose of epinephrine as opposed to withholding that dose. We have no disagreement about aggressive treatment of asthma concurrently, and in fact we think that point should be emphasised. However families reading this commentary may become more fearful, than they currently are, about admin- istering epinephrine. We know that epine- phrine is not always life saving even when administered in a timely fashion, however withholding it surely must increase the risk of calamity. Over dosing certainly may occur, but it seems more likely that an overdose would be administered by medically trained personnel than by parents. The over prescription of epinephrine is a debatable issue, however it seems a small price to pay, with a low risk, in order to save even one young life. Finally, we are very concerned that families will interpret this paper to mean that death from anaphylaxis is very unlikely, and therefore they may relax their vigilance. If families of younger children become less con- cerned when their children become adoles- cents it may be difficult to institute a good public education program. This is contrary to the opposite of the goal of education programs in the US (The Food Allergy and Anaphylaxis Network, www.foodallergy.org) and UK (The Anaphylaxis Campaign) aimed at making individuals with food allergy and the general population more aware of the problem and the potential for mortality. It is truly unfortu- nate that we cannot accurately identify all of the individuals who die during allergic reac- tions to food and use this information to do a better job of preventing these tragedies. We must continue our campaigns of education of medical professionals and the public, and we must be certain that emergency treatment is available when and where it is needed. J O’B Hourihane Wellcome Trust Clinical Research Facility, Southampton University Hospitals NHS Trust, Southampton, UK D Reading The Anaphylaxis Campaign, PO Box 275, Farnborough, Hampshire, UK P Smith Brisbane, Australia G Lock St Mary’s Hospital, London, UK D Hill Department of Allergy, Children’s Allergy Centre, Royal Children’s Hospital, Parkville, VIC 3052, Australia A Munoz-Furlong The Food Allergy & Anaphylaxis Network, 10400 Eaton Place, Fairfax, VA 22030, USA S A Bock National Jewish Medical and Research Center, Department of Paediatrics, University of Colorado Health Sciences Center, Denver, CO, USA Correspondence to Dr Bock; Bockdoc@aol.com References 1 MacDougall CF, Cant AJ, Colver AF. How dangerous is food allergy in childhood? The incidence of severe and fatal allergic reactions to foods. Arch Dis Child 2002;86:2236–9. 2 Yocum MW, Butterfield JH, Klein JS, et al. Epidemiology of anaphylaxis in Olmstead County: A population based study. J Allergy Clin Immunol 1999;104:452–6. 3 Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001;107:101–7. 4 Bock SA. The incidence of severe adverse reactions to food in Colorado. J Allergy Clin Immunol 1992;90:683–5. 5 Sampson HA. Death from allergy. N Engl J Med 2002;346:1294–8. Authors’ reply We thank Bock et al for their interest in our article. We respect their views on the interpretation of the data but it is of course for each reader to come to their own opinion on these. We would like to respond to their com- ments on the accuracy and validity of our data. Did our paper under ascertain deaths? Bock et al base their concerns on our methods of case ascertainment and on comparison with another study. We cannot be certain about this but the text indicated we used many sources and spoke to many experts in the field. We agree we did not search local newspapers but this would have been almost impossible as few were on CD-ROM in the 1990s. As mentioned, we did search national newspapers and all cases we came across were already known through one of our other sources. Finally, since publication, no-one has told us of a case we appear to have missed. We specifically studied children up to 15 years because this is the group we were inter- ested in. Many recommendations on risks to children are based on inferences from data covering all ages and we wanted to bring a proper paediatric perspective. Indeed the interpretation Bock et al give to the paper they cite is grossly misleading. They suggest extrapolation to a US population would lead to 200 deaths from food each year yet the paper, in which there is only one death (occurring during exercise), covers all ages and reactions to all allergens, not just food. The issue of whether asthma deaths may have been precipitated by food is an important question which we addressed “If a child’s symptoms are only asthmatic and no allergen is suspected, then there is no means for attributing such reactions to food or for knowing if a causal link exists”. Furthermore, such deaths will never have been reported in surveys of food allergy in other countries or in other age groups. No group has been able to address this question satisfactorily and it is a key area for further research. We are not sure we agree that children, who have self administered epinephrine, often do not go to hospital. However we do not know the proportion and said as much, excluding this group from our definition of severity. Finally we agree that education of profes- sionals and the public should continue based on the best data available. This must include those parents whose children are truly at high risk as well as those many parents that think any immediate hypersensitivity reaction to food means their child is at high risk of an allergic death; when in reality the risk, in the absence of asthma, seems to be small. Different parents will come to different views about how to proceed faced by a severe but very small risk, just as we all do in many aspects of our lives. C MacDougall Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, UK A Cant Paediatric Immunology and Infectious Diseases Unit, Newcastle General Hospital, UK Correspondence to Dr Colver; allan.colver@ncl.ac.uk Reference 1 Yocum MW, Butterfield JH, Klein JS, et al. Epidemiology of anaphylaxis in Olmstead County: a population based study. J Allergy Clin Immunol 1999;104:452–6. Physiologic management of DKA Inward and Chambers provide a provocative description and discussion of the continuing confusion regarding the issues surrounding rehydration and treatment of the pediatric patient with diabetic ketoacidosis (DKA). They review some of the key issues that link fluid therapy to complications from brain swelling, and question the appropriateness of using a volume of fluid calculated by “maintenance plus deficit”, calling for a second revolution in the management of DKA. In the accompanying commentary, Edge makes sev- eral statements concerning fluid therapy in DKA, including that “DKA is associated with severe fluid losses”, that “any guidelines for fluid and electrolyte management must be simple to calculate”, that administration of fluid is a risk factor for lateral spinal complica- tions, and that despite published data and “changes in protocols”, there is no evidence that the “incidence of cerebral oedema has changed over the past 20 years”. It is our opinion that the problem in the rehydration of the pediatric patient with DKA
does not lie in assigning a maintenance fluid allotment. Rather, the source of error lies largely with failure to accurately estimate the volume of deficit and the tendency to automatically assume a severe degree of dehydration. From our experience with over 450 consecutive patients with severe and moderate dehydration (serum osmolality ≤285 mOsm/kg or serum sodium <130 mEq/L), diabetic ketoacidosis (DKA) or diabetic or osmotic nonketotic hyperosmolar hyperglycemic state (DNKH), we found that significantly less redness and swelling occurred when infants were immunised using the longer 23 gauge 25mm (blue hub) needle than with the shorter 25 gauge 19mm (orange hub) needle was used. The magnitude of the reductions was substantial. The position statement is correct to note that in our study the difference in tenderness did not reach statistical significance. However we believe our study still has spanned 14 years and nearly 500 consecutively managed cases. We remain available to participate in any endavour to improve the care of the paediatric patient in DKA.

G D Harris, I Fiordalisi
Brodsky School of Medicine at East Carolina University, Greenville, North Carolina, USA

Correspondence to Dr Harris; 

References


The Position Statement on Injection Technique

The Position Statement on Injection Technique (March 2002, Royal College of Paediatrics and Child Health) discusses needle size and length for childhood immunisation. It concludes that there would seem to be insufficient evidence to advise any recommendation to change current practice in the use of smaller gauge needles. As the authors of a research study that aimed to provide some evidence base for immunisation practice we would like to respond to this.1

Our study of 119 babies aged 4 months receiving their third dose of DPT/Hib vaccine found that significantly less redness and swelling occurred when infants were immunised using the longer 23 gauge 25mm (blue hub) needle rather than when the shorter 25 gauge 19mm (orange hub) needle was used. The magnitude of the reductions was substantial. The position statement is correct to note that in our study the difference in tenderness did not reach statistical significance. However we believe our study still
justifies a recommendation for the use of the longer needle for immunisation in 4 month old infants.

We believe the non-significant difference in tenderness with the different needles must be interpreted with caution, and should not be taken as a rationale for ignoring the significant benefits in terms of reduced redness and swelling. Tenderness was in fact reduced by the same relative amount as redness, but as tenderness occurred less frequently, the results were not formally statistically significant. We have used Bayesian analyses (using an “uninformative” prior distribution) to formally compute the chance that there is a clinically significant reduction (of at least 25% as specified in the protocol) in tenderness between the long and short needles. At six hours the probability of a clinically significant decrease in tenderness with the longer needle is 73%, whereas the chance of a clinically significant increase is only 2%. The evidence is therefore clearly in the direction of the longer needle causing less harm.

We recognise the need for further evidence on which to base immunisation practice at each of the infant immunisation ages. To this end, we are now conducting a randomised controlled trial involving over 600 infants aimed at providing a definitive answer. In the meantime, we reiterate our recommendation to practitioners to use the longer needle for immunising 4 month old infants.

L Diggle
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK

J Deeks
Centre for Statistics in Medicine, Institute of Health Sciences, University of Oxford, Oxford OX3 7LF, UK

Correspondence to: Linda Diggle; linda.diggle@paediatrics.ox.ac.uk

Reference

The paper by Parkin et al in the September issue of Archives (Arch Dis Child 2002;87:221–2) was missing acknowledgements. The following paragraph should have been included:

Rita Arseneault, Audrey Bell-Peter, Diana Cohen, Pauline Matthews, Suzanne Stewart, and Olwen Tennis participated in patient enrollment and data collection. Derek Stephens assisted in statistical consultation. Rose Cheung and Carol Collins did the immunofluorescence microscopy and virus isolation tests. Dr Raymond Tellier oversaw virus testing for part of the time while he was on service.

Funding: This work was supported in part by grants from the Hospital for Sick Children Research Institute and the American Academy of Pediatrics. The Paediatric Outcomes Research Team is supported by a grant from the Hospital for Sick Children Foundation.